Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis

Detalhes bibliográficos
Autor(a) principal: Ferret-Sena, Véronique
Data de Publicação: 2022
Outros Autores: Capela, Carlos, Macedo, Ana, Salgado, António Vasco, Derudas, Bruno, Staels, Bart, Sena, Armando
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/19063
Resumo: Fingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease.
id RCAP_031bc429aba5662f1f23bb405d7ccc9b
oai_identifier_str oai:sapientia.ualg.pt:10400.1/19063
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosisFingolimodPeroxisome proliferator-activated receptors (PPAR)Cluster of differentiation 36 (CD36)LipoproteinsMultiple sclerosisFingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease.Frontiers MediaSapientiaFerret-Sena, VéroniqueCapela, CarlosMacedo, AnaSalgado, António VascoDerudas, BrunoStaels, BartSena, Armando2023-02-13T10:15:57Z2022-122022-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/19063eng1662-509910.3389/fnmol.2022.1077381info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:31:28Zoai:sapientia.ualg.pt:10400.1/19063Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:08:44.569285Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
title Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
spellingShingle Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
Ferret-Sena, Véronique
Fingolimod
Peroxisome proliferator-activated receptors (PPAR)
Cluster of differentiation 36 (CD36)
Lipoproteins
Multiple sclerosis
title_short Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
title_full Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
title_fullStr Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
title_full_unstemmed Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
title_sort Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
author Ferret-Sena, Véronique
author_facet Ferret-Sena, Véronique
Capela, Carlos
Macedo, Ana
Salgado, António Vasco
Derudas, Bruno
Staels, Bart
Sena, Armando
author_role author
author2 Capela, Carlos
Macedo, Ana
Salgado, António Vasco
Derudas, Bruno
Staels, Bart
Sena, Armando
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Ferret-Sena, Véronique
Capela, Carlos
Macedo, Ana
Salgado, António Vasco
Derudas, Bruno
Staels, Bart
Sena, Armando
dc.subject.por.fl_str_mv Fingolimod
Peroxisome proliferator-activated receptors (PPAR)
Cluster of differentiation 36 (CD36)
Lipoproteins
Multiple sclerosis
topic Fingolimod
Peroxisome proliferator-activated receptors (PPAR)
Cluster of differentiation 36 (CD36)
Lipoproteins
Multiple sclerosis
description Fingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease.
publishDate 2022
dc.date.none.fl_str_mv 2022-12
2022-12-01T00:00:00Z
2023-02-13T10:15:57Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/19063
url http://hdl.handle.net/10400.1/19063
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1662-5099
10.3389/fnmol.2022.1077381
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133334277718016